If you or your loved one are seeking a seamless and effective solution for prostate issues look no further

In October 2020, I took the lead of the non muscle invasive bladder cancer,  and created the first guidelines for bladder cancer in East Sussex with the aim to minimise waiting times and ensure adequate delivery care with the latest international standards. Only through working with a dynamic team this could be sustained. 

There is a dedicated bladder pathway multidisciplanry meeting where each case is discuss in depth. 

Since taking over the care of bladder cancer I shortened the pathway for diagnosis and treatment delivered to well below the national recommended guidelines.  This has impacted in the long term as early diagnosis of bladder cancer and treatment (bladder instillations of chemotherpay like mitomycin or epirubicin or immunotherpay like BCG) does decrease the risk of recurrence and progression of the cancer.

Picking up earlier the most aggressive bladder cancer means early radical treatment (radiotherapy or surgery)  results in better overall survival.  

 My thesis was focused on antibiotic stewardship. I reviewed over 400,000 urine cultures and antibiotic sensitivities. The findings paved further antibiotic stewardship principles.

Even though urinary tract infections are commonly associated with females  they can happen in males too. 

The biggest treath is the development of antibiotic resistsance. It is crucial that non antibiotic treatments are exhausted first.  

In the old days cranberry juice/ supplements have been assocaited with alleged natural resolution but studies have shown they do not work. 

Lifestyle changes are key. The commonest issue is lack of drinking adequate fluids throughout the day resolves most of the reoccuring infections.  Try to orgnaise an infection diary in order to identify any link that is triggering the urinary infection. Make sure to send everytime the urine to the lab to be cultured as it is very important to know what bacteria is causing the infection or to exclude an infection (there are other conditions like interstitial cystitis that can mimic a urinary tract infection).  

I continued to build on the enhanced recovery startup for our major  urology surgical procedures. This was only achievable through the collaboration of different  healthcare professionals. 

This lead to better patient outcome, less complications, decrease in pain medication, reduced hospital stay and faster recovery. The lessons learnt from prostate cancer robotic prostatectomy and cystectomy have been extended to all other surgeries.

When I started working in Eastbourne a patient who underwent radical removal of the bladder length of hoispital stay was around 2 to 3 weeks. It took three years of hard work and collaboration and today I am proud to say that the length of stay is between 5 to 7 days.

Currently we are working to establish day case robotic prostatectomy.

We do have a enhnaced recovery teaching day that was halted due to COVID restrictions but from 2023 this will kick back in order to share the lessons learnt with all those who want to see an improvement in their delivery of care.

Localised low risk prostate cancer (majority of Gleason 6 and some of Gleason 7) are enrolled in a structured programme called Active Surveillance. Studies have shown that these types of prostate cancers are often overtreated with minimal benefit in long term. 

During the surveillance one is asked to have regular PSA blood tests, interval MRI scans and if needed prostate biopsies. Treatment is offered if your cancer may be progressing, or you decide you want treatment as  one may feel uncomfortable to have a cancer that is closely watched. 

In the world different hospitals have different surveillance programmes. In East Sussex there was no protocol and I have worked over a period of 8 months designing a protocol to meet the patient needs within national and international guidelines. 

Currently we have a dedicated prostate cancer nurse who I support to manage patients with prostate cancer on active surveillance.

I have been selected by Prostate Cancer UK as a prostate clinical champion to undertake projects in improving the quality of care and life of prostate cancer patients. This is a great honour.

 Prostate cancer is common. In the UK about 48,000 men are diagnosed each year. Prostate cancer is more common in older men. The risk  of prostate cancer at a young age increases if you are Black or have a strong family history of prostate cancer or maternal breast or ovarian cancer.  

Being a clinical champion has moulded my leadership skills, helped me understand better the challeneges that different healthcare professionals undergo in trying to ameliorate the quality of care to prostate cancer patients whether its from diagnosis, surveillance, radiotherapy, homrones, surgery or novel treatments. 

Self reflection, communication, building networks throughout UK and becoming a better leader translates in better prostate cancer care.     

  I have trained our surgical care practitioner who performs all the bedside assistance for major robotic surgery for kidney cancer, bladder cancer and prostate cancer.  I taught and supported our surgical care practitoiner in learning basic surgery and as well in becoming independent in running their own list of minor urological procedure to cut down on NHS waiting time. I was his supervisor for his two year masters degree.  

I currently support and train the urology diagnsotic nurses in managing the two wait week referrals for prostate / bladder cancer.  Many patients are referred to our department because od an elevated PSA blood test, suspicious prostate exam, blood with urine who need a fast diagnosis in order to detect cancer early and treat early.

I support the urology cancer nurse specialists (especially the prostate cancer and bladder cancer). 

I train junior and senior doctors (the next consultants) both academically and surgically in order to strengthen the future generation of urologists and doctors.

 Together with my colleagues we have looked at catheter care delivery in Eastbourne hospital.

 This lead to creation of teaching and care practices regarding catheter care ensuring improved quality of care delivery to our patients suffering from prostate and/or bladder issues leading to difficulty in emptying their bladder.

Such achievements will lead to better catheter care, a solid education foundation for our staff and students.   

 Through a collaborative effort with another hospital, and with my team we have introduced a self-removal approach for catheters in patients recovering from Robotic Prostate Removal.

As a result, patients referred from across the South East for their radical prostatectomy at our Trust can now bypass the need to revisit the hospital for catheter removal post-operation.

This choice not only saves valuable time and reduces clinic visits but also curtails travel expenses and parking costs for patients. 

By reducing the number of people in the Urology Clinic, we enhance patient dignity and privacy during their recovery period. It's worth mentioning that patient travel contributes to about five per cent of the NHS's carbon footprint.

 I am curretnly setting the protocols and setting up support through all the stages for patients to undergo day case TURBT at our Hospital.  

This means that the patient undergoes the procedure and is discharged from the hospital on the same day, without the need for an overnight stay. This approach is possible for selected patients who meet specific criteria, such as having a low-risk tumor and being in good overall health.

The benefits of day case TURBT include lower hospitalisation costs, lower risk of hospital-acquired infections, and greater convenience for the patient.